bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.

Published

Journal Article

The bcl-2 proto-oncogene and the p53 tumor suppressor gene are important determinants of tumor cell susceptibility to apoptosis. bcl-2 and mutant p53 proteins inhibit apoptosis in vitro and can provide prognostic information in certain tumor types. We analyzed bcl-2 and p53 expression in archival pancreatic (n = 35) and ampullary (n = 6) adenocarcinomas, resected for cure, and their relationship to overall survival. Patients were treated with 5-fluorouracil and irradiation either pre- (n = 21) or postoperatively (n = 15); 5 patients received surgery alone. Using specific monoclonal antibodies, cytoplasmic bcl-2 and nuclear p53 proteins were detected in 22 of 40 (55%) and 20 of 37 (54%) tumors, respectively. No relationship was found between bcl-2 and p53 expression. Neither bcl-2 nor p53 correlated with histological response to preoperative chemoradiation. Lymph node involvement predicted poor overall survival (P = 0.02). A trend toward improved survival was seen in well-differentiated (P = 0.08) tumors and in those with increased bcl-2 expression (P = 0.06). p53 expression was not related to clinical outcome. In a multivariate analysis, nodal status was the single most important predictor of overall survival. Of note, the combined variable of bcl-2 expression and histological grade was a stronger prognostic variable than nodal status alone. Unlike nodal status, these features can potentially be evaluated in preoperative biopsy specimens.

Full Text

Duke Authors

Cited Authors

  • Sinicrope, FA; Evans, DB; Leach, SD; Cleary, KR; Fenoglio, CJ; Lee, JJ; Abbruzzese, JL

Published Date

  • December 1996

Published In

Volume / Issue

  • 2 / 12

Start / End Page

  • 2015 - 2022

PubMed ID

  • 9816161

Pubmed Central ID

  • 9816161

International Standard Serial Number (ISSN)

  • 1078-0432

Language

  • eng

Conference Location

  • United States